Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial

Oncology

Volumn 69, Issue 5, 2005, Pages 384-390

  Souglakos, J ^a   Pallis, A ^a   Kakolyris, S ^a   Mavroudis, D ^a   Androulakis, N ^a   Kouroussis, C ^a   Agelaki, S ^a   Xenidis, N ^a   Milaki, G ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Elderly patients; Irinotecan; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

AGED; ANEMIA; ARTICLE; ASTHENIA; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENESCENCE; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 29144469349     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089992     Document Type: Article

References (35)

1. Black RJ, Bray F, Ferlay J, Parkin DM: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-1107.
2. American Cancer Society: Cancer facts and figures - 2000. Atlanta, GA: ACS, 2000.
3. Reis LAG, Eisner MP, Kosary CL: SEER Cancer Statistics Review, 1973-1998. Bethesda, National Cancer Institute, 2001.
4. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
5. The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
6. Kohne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
7. Poon MA, O'Connel MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
8. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;14:808-815.
9. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-5082.
10. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y: Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivates presently in clinical trials. J Natl Cancer Inst 1994;86:836-842.
11. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herait P, Bleiberg H: Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999;35:54-59.
12. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 2000;355:1041-1047.
14. rd, Engelkinget C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E: Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-3178.
15. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30:A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
16. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
17. Cox DR: The Analysis of Binary Data. London, Methnen, 1970.
18. Hutchins LF, Unger JM, Humble CG, Coltman CA Jr, Albain KS: Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
19. Mor V, Masterson-Allen S, Goldberg RJ, Cummings FJ, Glicksman AS, Fretwell MD: Relationship between age at diagnosis and treatment received by cancer patients. J Am Geriatr Soc 1985;33:585-589.
20. Saltz LB, Douillard J, Pirotta N, Awad L, Elfring GL, Gruia G, Locker P, Alakl M, Knight R, Miller L: Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs. F alone as first line treatment of metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol (abstract No 938) 2000;19:242a.
21. Vestal RE: Aging and pharmacology. Cancer 1997;80:1302-1310.
22. Walsh SJ, Begg CB, Carbone PP: Cancer chemotherapy in the elderly. Semin Oncol 1989;16:66-75.
23. Balducci L, Mowry K: Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992;6:62-68.
24. Balducci L, Extermann M: Cancer chemotherapy in the older patient: What the medical oncologist needs to know. Cancer 1997;80:1317-1322.
25. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
26. Brower M, Asbury R, Kramer Z: Adjuvant chemotherapy for colorectal cancer in the elderly: Population-based experience (abstract). Proc Am Soc Clin Oncol 1993;12:195.
27. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ: Age and sex are independent predictors of 5-fluorouracil toxicity: Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
28. Zalcberg J, Kerr D, Seymour L, Palmer M: Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 1998;34:1871-1875.
29. Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A: Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992;28:1817-1820.
30. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-340.
31. Aschele C, Guglielmi A, Tixi LM, Bolli E, Mori AM, Lionetto R, Rosso R, Sobrero A: Adjuvant treatment of colorectal cancer in the elderly. Cancer Control 1995;2(suppl 1):36-38.
32. Daniele B, Rosati G, Tambaro R, Ottaiano A, De Maio E, Pignata S, Iaffaioli RV, Rossi A, Manzione L, Gallo C, Perrone F: First-Line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: A phase II study. J Clin Gastroenterol 2003;36:228-233.
33. Tournigand C, Louvet C, Quinaux E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. J Clin Oncol 2004;22:229-237.
34. Souglakos J, Athanasiadis A, Ginopoulos P, Giannakakis Th, Syrigos K, Kouroussis Ch, Androulakis N, Kakolyris S, Vardakis N, Georgoulias V: Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5-FU) (FOLFOXIRI) compared with CPT-11, LV, and 5-FU (FOLFIRI) as first-line treatment for metastatic colorectal cancer: Preliminary safety and efficacy results of a multicenter randomized trial. Proc Am Soc Clin Oncol (abstract no 608), 2002;21:153a.
35. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR: A randomized controlled trial of Fluorouracil plus Leucovorin, Irinotecan, and Oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.